PROFESSIONAL EDITION

The largest community of pharma leaders

Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)

SAN LEANDRO, Calif.–(BUSINESS WIRE)–Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the first interim analysis results from its ongoing FIERCE-22 trial of vofatamab in patients with metastatic bladder cancer. Results were presented at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting. FIERCE-22 is a Phase 1b/2 trial evaluating vofatamab, a FGFR3-targeted antibody, in combination with pembrolizumab, an immune checkpoint…

 

http://www.businesswire.com/news/home/20190603005439/en/Rainier-Therapeutics-Announces-Results-Interim-Analysis-FIERCE-22/

Recent Articles